Farewell to chemotherapy! Ibuprofen, a new leukemic drug, reaches the end of phase 3

Source: Wuxi apptec May 25, 2018 today, abbvie announced that its phase 3 clinical trial, illuminate (pcyc-1130), has reached the main end point of PFS improvement This study evaluated the efficacy of imbruvica (ibrutinib) combined with gazyva (obinutuzumab) in the treatment of primary patients (the most common adult leukemia) with chronic lymphoid leukemia or small Lymphoid Lymphoma (CLL / SLL) CLL, the most common form of leukemia in adults, is a cancer that develops from cells in the bone marrow that later mature into certain white blood cells (lymphocytes) Although these cancer cells start in the bone marrow, they later spread into the blood The number of CLL patients in the United States is about 115000, with about 19000 new cases each year Sll is a slow-growing lymphoma, biologically similar to CLL, in which too many immature leukocytes lead to the enlargement of lymph nodes CLL / SLL mainly occurs in the elderly The median age at the time of diagnosis is 71 years old At present, the treatment of CLL / SLL is still limited to chemotherapy Once the disease relapses, the total survival time of these patients is usually only 2 to 3 years There are also huge medical needs to be met in this area Imbruvica (ibrutinib), a first-in-class oral, once-a-day treatment brought about by the collaboration of pharmacyclics and Janssen, works mainly by blocking the Brunton's tyrosine kinase (Btk) Btk is a key signal molecule in B cell receptor signal complex, which plays an important role in the survival and transmission of malignant B cells and other serious debilitating diseases Imbruvica can block signals indicating the proliferation and transmission of malignant B cells At present, imbruvica has been approved by the FDA for use in six different patient groups: CLL, SLL, waldenstein megaglobulinemia (WM), as well as mantle cell lymphoma (MCL), marginal zone lymphoma (MZL) and chronic graft-versus-host disease (cGVHD), which have been treated It is worth mentioning that the drug, which is made by Kant group and Hequan pharmaceutical, was launched in China last year to treat CLL / SLL / MCL patients who have received at least one treatment The illuminate study was a randomized, multicenter, open label, three-phase study to evaluate the efficacy of the combination of imabruvica and gazyva in the treatment of CLL / SLL patients In this study, the patients were randomly treated with imbruvica 420 mg plus gazyva 1000 mg for six consecutive cycles, or with nitrogen mustard benzoate plus gazyva 1000 mg The primary end point was PFS evaluated by the Independent Review Committee (IRC), and the secondary end point included the overall response rate and the minimal residual lesion (MRD) negative response rate The results showed that compared with the control group, the patients who received imbruvica plus gazyva had significant differences in PFS in clinical and statistical aspects, reaching the main end point of the study "We are optimistic about the main results of the illuminate study and the fact that imbruvica plus obinutuzumab shows a significant improvement in progression free survival compared to obinutuzumab plus nitrogen mustard benzoate This combination therapy is currently recommended as class 1 therapy by NCCN guidelines, "said Dr danelle James, head of clinical science, pharmacologics, Aberdeen." since its launch nearly five years ago, imbruvica has been considered as an important treatment option for CLL / SLL patients At the same time, we now have CLL's long-term five-year data We are committed to developing the full potential of imbruvica, whether alone or in combination, for the treatment of various B-cell blood cancers " "We are pleased to see the positive results of the combination of ibrutinib and obinutuzumab This combination without chemotherapy provides a potential new treatment option for patients with chronic lymphoid leukemia, "said Dr John Gribben, chief researcher of illuminate research and professor of oncology at Barts Cancer Research Institute in the UK." I'm glad to see the continuous progress of the treatment mode of blood cancer, and each progress can provide a better treatment standard for patients " Based on these data, pharmacyclics and Janssen are working with regulators to advance the regulation of the treatment If approved, it will be the first CD20 combination therapy that does not include chemotherapy in the first-line CLL treatment We are looking forward to this day as soon as possible to bring good news to the patients!